Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

1(50.0%)

N/A

1(50.0%)

2Total

Phase 4(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT02374450Completed

A Surveillance Study of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine

Role: collaborator

NCT04029454Not ApplicableCompleted

Neovac 2 Burkina Faso: Impact of the Integration of Hepatitis B Birth Dose Vaccine Into the Infant Immunization Schedule

Role: collaborator

NCT02983487Completed

Pertussis Immunization Programs in Low Income Countries

Role: collaborator

NCT01747369Unknown

Surveillance of Hospitalised Pneumonia and Bacterial Meningitis in Tône District, Togo, 2010-2013

Role: lead

NCT01577771Phase 4Completed

Immunogenicity and Reactogenicity of PCV13 Among Infants and Children in Burkina Faso

Role: lead

All 5 trials loaded